A report published October 8, 2026, said London-based Isomorphic Labs was in early discussions about raising funding at a possible valuation of $40 billion to $50 billion. No agreement had been reached by the time of the report.
The reported talks concern company value
The $40 billion–$50 billion range describes a possible valuation of the company—the estimated worth used in a financing negotiation. It is not the amount of cash raised in a round; financing proceeds are a separate figure.
AI drug design is the company's focus
Isomorphic Labs uses AI to design potential medicines, building on Google DeepMind’s AlphaFold technology for predicting protein structures. Its approach includes modeling how molecules may interact with biological targets before laboratory testing. Reported work includes potential treatments for cancer and immune disorders, alongside collaborations with Eli Lilly, Novartis, and Johnson & Johnson.
Earlier funding and the clinical-trial target
Earlier reported financing included a $600 million raise in March 2025 and a $2.1 billion Series B in May 2026, totaling about $2.7 billion.
As of the October 8 report, Isomorphic Labs had not tested its own drug candidates in humans. The company was targeting its first clinical trials by the end of 2026.
